Literature DB >> 1003522

In vivo distinction between a target cell for Friend virus (FVP) and murine hematopoietic stem cells.

A G Nasrallah, M P McGarry.   

Abstract

Busulphan (BU) treatment of DBA/2 mice with hypertransfusion (HT)-induced polycythemia resulted in an ablation of detectable hematopoietic stem cells (CFUS) in pooled marrow from the long bones. Daily injections of erythropoietin (EP) stimulated an EP-responsive population of cells in the absence of detectable CFUS. Mice treated with BU and EP and having HT-induced polycythemia were inoculated with the polycythemia-inducing strain of Friend virus (FVP) and determinations were made for the presence of tumor colony-forming units (tCFU). No change in CFUS/10(6) bone marrow cells was detected as a result of EP treatment. However, tCFU were increased more than 100-fold in HT-BU-EP-treated mice compared with saline-treated controls. The demonstration of tCFU in mice in which CFUS were not detectable indicated that this leukemogenic effect of FVP could occur in the absence of the pluripotent stem cell. Furthermore, the increased numbers of this FVP target cell in the EP-stimulated, BU-treated mice with HT-induced polycythemia supported the model licating the target for this effect in the EP-responsive cell population.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003522     DOI: 10.1093/jnci/57.2.443

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Studies on the target cell for the Friend virus (FV-P strain) using the CFU-E technique.

Authors:  U Opitz; H J Seidel
Journal:  Blut       Date:  1978-10-13

2.  Heteroduplex analysis of molecular clones of the pathogenic Friend virus complex: Friend murine leukemia virus, Friend mink cell focus-forming virus, and the polycythemia- and anemia-inducing strains of Friend spleen focus-forming virus.

Authors:  M A Gonda; J Kaminchick; A Oliff; J Menke; K Nagashima; E M Scolnick
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.